Published • loading... • Updated
EC Approves AbbVie’s Tepkinly Combination for Follicular Lymphoma
The approval is based on Phase 3 data showing a 79% lower risk of progression or death and a 96% overall response rate, Genmab said.
Summary by Verdict Hospital
4 Articles
4 Articles
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in the second-line setting, offering a chemotherapy-free optionIn the Phase 3 EPCORE® FL-1 trial,…
·Waterloo, United States
Read Full Article
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in
Verdict HospitalReposted by 
Pharmaceutical Business review
Pharmaceutical Business reviewEC approves AbbVie’s Tepkinly combination for follicular lymphoma
The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.The post EC approves AbbVie’s Tepkinly combination for follicular lymphoma appeared first on Hospital Management.
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
